The NHC concentration in maternal blood and conceptus was above the average median inhibitory concentration (IC50) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV
Molnupiravir is a prodrug of the synthetic nucleoside derivative N 4-hydroxycytidine and exerts its antiviral action by introducing copying errors
used in the paxlovid trial 3 and molnupiravir trial, 4 our effect size does not change importantly (relative risk [RR] 0 The route to an effective antiviral treatment against SARS-CoV-2 has been marked by dozens of negative clinical trials, with thousands of patients across the globe enrolled in futile clinical trials
1 Molnupiravir has not yet been approved in Europe,2 and orders were recently cancelled in France
and Australia
59% for 30 days, an 46
[PMC free article] [Google Scholar] 14
report the results of the PANORAMIC arm in which molnupiravir plus usual care was compared with usual care alone as an early treatment for community-based adults with COVID-19 at higher risk of adverse outcomes